Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Human Genetics01:28

Human Genetics

566
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
566
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

13.4K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
13.4K
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

254
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
254
Assessment of the Cardiovascular System I: Subjective Data01:23

Assessment of the Cardiovascular System I: Subjective Data

338
A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
338
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

2.8K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.8K
Biopharmaceutics and Pharmacokinetics: Overview01:28

Biopharmaceutics and Pharmacokinetics: Overview

2.0K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Artificial Intelligence-Enabled Cardiac Function Estimation from Phone Videos of Echocardiograms.

medRxiv : the preprint server for health sciences·2026
Same author

Harmonizing standards and resources for the medical genome.

Nature·2026
Same author

Population-scale detection of methylation outliers from long-read genome sequencing.

medRxiv : the preprint server for health sciences·2026
Same author

Building an Interoperable Rare Disease Multi-omic Resource: The GREGoR Data Model and Dataset.

bioRxiv : the preprint server for biology·2026
Same author

Multi-Omic, Multi-Tissue Responses to Acute Exercise in Sedentary Adults: Findings from the Molecular Transducers of Physical Activity Consortium.

bioRxiv : the preprint server for biology·2026
Same author

Author Correction: Biallelic variants in the noncoding RNA gene RNU4-2 cause a recessive neurodevelopmental syndrome with distinct white matter changes.

Nature genetics·2026
Same journal

Correction to "Physicians' Perceptions of Prescribing in Pregnancy and Package Inserts: A Survey of General and Hub Hospitals in Japan".

Clinical and translational science·2026
Same journal

Development of Core Competencies in Clinical Data Science Graduate Education: A Follow-On Tutorial to From Clinical Data Management to Clinical Data Science: Time for a New Educational Model.

Clinical and translational science·2026
Same journal

Population Pharmacokinetic, Exposure-Response Efficacy and Safety Analyses of Favezelimab in Patients With Solid Tumors.

Clinical and translational science·2026
Same journal

Development of a Biphasic Modified-Release Ibuprofen Tablet Formulation: Single-Dose and Multiple-Dose Pharmacokinetics and Food-Effect Studies.

Clinical and translational science·2026
Same journal

Circulating M-MDSC Expansion During Therapy Associates With Treatment Response in Multiple Myeloma: A Longitudinal Observational Study.

Clinical and translational science·2026
Same journal

PBPK Modeling and Clinical Data Reveal Reduced Impact of CYP3A4 and CYP2C9 Inhibitors on Elimination of Siponimod.

Clinical and translational science·2026
See all related articles

Related Experiment Video

Updated: Jul 2, 2025

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
07:15

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

11.0K

Knowledge and attitudes on implementing cardiovascular pharmacogenomic testing.

Callan Russell1, MaryAnn Campion1, Megan E Grove2

  • 1Department of Genetics, Stanford University, Stanford, California, USA.

Clinical and Translational Science
|February 29, 2024
PubMed
Summary
This summary is machine-generated.

Cardiology providers show moderate pharmacogenomics knowledge but limited test ordering experience. They are interested in integrating pharmacogenomic testing, especially panels, into cardiovascular care.

More Related Videos

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
02:47

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

1.3K
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.1K

Related Experiment Videos

Last Updated: Jul 2, 2025

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
07:15

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

11.0K
Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
02:47

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

1.3K
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.1K

Area of Science:

  • Cardiovascular Medicine
  • Pharmacogenomics
  • Clinical Genetics

Background:

  • Pharmacogenomics offers potential benefits in drug therapy, including improved efficacy and reduced adverse events.
  • Provider knowledge and adoption of pharmacogenomic testing vary significantly across different medical specialties.
  • Cardiovascular medications are frequently affected by genetic variations, highlighting the need for pharmacogenomic insights in cardiology.

Purpose of the Study:

  • To assess the knowledge, attitudes, and perceived barriers among cardiology providers regarding the implementation of clinical pharmacogenomic testing.
  • To understand cardiology providers' familiarity with pharmacogenomics and their willingness to order and interpret pharmacogenomic tests.
  • To explore preferences for pharmacogenomic testing formats (panel vs. single gene) within cardiology practice.

Main Methods:

  • An online survey was distributed to 61 cardiology providers, including pharmacists, physicians, genetic counselors, and nurses.
  • The survey assessed participants' prior genetics education, familiarity with pharmacogenomics, experience with ordering tests, and attitudes towards implementation.
  • Data analysis focused on identifying knowledge gaps, interest levels, and barriers to adopting pharmacogenomic testing in cardiovascular care.

Main Results:

  • While most providers had some genetics education, only 52% felt prepared to order pharmacogenomic tests.
  • 66% of respondents were familiar with pharmacogenomics, with genetic counselors showing the highest familiarity.
  • Only 15% had ordered a test previously, but 36% were likely to in the future, with 89% interested in its incorporation into cardiovascular genetic testing. 84% preferred panel testing.

Conclusions:

  • Cardiology providers possess moderate familiarity with pharmacogenomics but have limited practical experience in ordering tests.
  • There is significant interest among cardiology providers in integrating pharmacogenomic testing, particularly panel-based approaches, into their clinical practice.
  • Barriers such as uncertainty about clinical utility and logistical challenges need to be addressed to facilitate wider adoption of pharmacogenomics in cardiovascular medicine.